Rockland Trust Co. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 159,704 shares of the company’s stock after buying an additional 7,172 shares during the quarter. Johnson & Johnson accounts for approximately 1.9% of Rockland Trust Co.’s portfolio, making the stock its 9th largest holding. Rockland Trust Co.’s holdings in Johnson & Johnson were worth $20,952,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. Virtus ETF Advisers LLC acquired a new position in Johnson & Johnson during the second quarter worth about $25,000. Krane Funds Advisors LLC purchased a new stake in shares of Johnson & Johnson in the second quarter valued at about $26,000. Crewe Advisors LLC lifted its holdings in shares of Johnson & Johnson by 725.9% in the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after purchasing an additional 196 shares in the last quarter. Permanens Capital L.P. lifted its holdings in shares of Johnson & Johnson by 50.0% in the second quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock valued at $42,000 after purchasing an additional 100 shares in the last quarter. Finally, Thor Advisors LLC purchased a new stake in shares of Johnson & Johnson in the first quarter valued at about $69,000. Institutional investors own 72.01% of the company’s stock.
Shares of JNJ traded up $3.18 on Friday, hitting $132.24. 2,245,488 shares of the stock traded hands, compared to its average volume of 6,702,304. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $347.95 billion, a P/E ratio of 16.17, a P/E/G ratio of 2.22 and a beta of 0.69. The stock’s 50 day moving average is $129.92 and its two-hundred day moving average is $135.00. Johnson & Johnson has a 1 year low of $121.00 and a 1 year high of $148.99.
Several analysts have issued reports on the stock. Morgan Stanley reaffirmed an “equal weight” rating and issued a $145.00 price target on shares of Johnson & Johnson in a report on Tuesday, August 27th. Barclays assumed coverage on shares of Johnson & Johnson in a report on Friday, June 21st. They issued a “hold” rating and a $140.00 price target on the stock. Goldman Sachs Group set a $169.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Tuesday, August 27th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Finally, Sanford C. Bernstein raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target on the stock in a report on Friday. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Buy” and a consensus target price of $151.00.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: How Do Investors Open a Backdoor Roth IRA?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.